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Case presentation
A 37-year-old man was transferred to Brigham and Women's Hospital
for evaluation of progressive renal failure. His medical history was notable
for intravenous drug use and heavy ethanol consumption but he denied
their use for the last 7 years. He had had at least one bout of alcoholic
hepatitis, which was diagnosed about 8 years previously.
The patient originally presented to his physician 2 years ago with
complaints of mild anorexia and fatigue. Workup at that time was
remarkable for slightly elevated liver enzymes and a serum creatinine of
1.2 mg/dl. Six weeks later he noted the onset of periorbital edema followed
by edema of the legs and a 20-pound weight gain. He consulted the
emergency room of a local hospital for these symptoms one year ago,
where he was noted to have elevated liver enzymes and a serum creatinine
that had risen to 1.7 mg/dl. Urinalysis revealed 4+ protein and 2+ blood
by dipstick; microscopic examination of the urinary sediment revealed red
blood cells too numerous to count, 5 to 10 white blood cells/high-power
field, and numerous hyaline and granular casts. He was referred to a
nephrologist.
At physical examination performed by the nephrologist 2 days later, his
pulse was 72 beats/mm; blood pressure, 160/110 mm Hg; and respirations
were normal. No oral lesions were present, and funduscopic examination
showed no abnormalities. The jugular venous pressure was estimated at 9
cm H20, and the thyroid gland was palpable without nodules. The chest
was clear; cardiac examination revealed a normal rhythm with a soft S4. A
grade II/IV systolic ejection murmur was audible. The abdomen was
distended and soft but without tenderness, and no masses were palpable;
bowel sounds were normal. The spleen was not detectable, but the liver
edge was palpable 4 cm below the right costal margin. The extremities
were remarkable for 3 + pitting edema up to the mid-portion of the calf.
The skin revealed a discrete, papular, erythematous rash.
Laboratory data included a white blood cell count of 30,200/mm3 with
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a normal differential count; hematocrit, 27.2%; and a platelet count of
171,000/mm3. The serum sodium was 132 mEq/liter; potassium, 4.6
mEq/liter; chloride, 97 mEq/liter; and bicarbonate, 19 mM/liter. The BUN
was 121 mg/dl and the serum creatinine, 4.6 mg/dl. The glucose level was
176 mg/dl. The alanine aminotransferase was 76 U/liter (reference range,
7 to 52 U/liter); aspartate aminotransferase, 24 U/liter (reference range, 9
to 30 U/liter); and lactic dehydrogenase, 418 U/liter (reference range, 107
to 231 U/liter). Total serum protein was 5.1 Wdl with a serum albumin of
3.5 gldl. The serum calcium was 8.7 mg/dl. Total cholesterol was 149 mg/dl.
The prothrombin time was 12,5 sec and the partial thromboplastin time,
23.6 sec. Urinalysis disclosed a pH of 5, and dipstick evaluation revealed
3+ protein and 3+ blood. The urinary sediment contained red blood cells
too numerous to count, with numerous dysmorphic forms and occasional
white blood cells. Several serologic tests were ordered, and the patient was
hospitalized for a renal biopsy.
A percutaneous renal biopsy was performed under local anesthesia and
ultrasound guidance. Two cores of renal tissue were examined by the
pathologist in the ultrasound suite for the presence of adequate cortical
tissue using a stereoscopic microscope. A small fragment of cortical tissue
with identifiable glomeruli was immediately fixed in glutaraldehyde/
paraformaldehyde mixture for ultrastructural analysis. A similar fragment,
placed in transport medium containing a buffered salt solution and
protease inhibitors, subsequently was processed for direct immunofluo-
rescence microscopy. The remaining tissue was fixed in buffered formal-
dehyde solution and processed for conventional light microscopy.
The sample processed for light microscopy included renal cortex and
outer medulla; 8 glomeruli were present. The tufts of all glomeruli
appeared enlarged and showed prominent hypercellularity (Fig. IA). Most
cells within the tuft were mononuclear, but several neutrophils also were
identified, The inflammatory cells appeared within the confines of the
capillary loops; others were located in the expanded mesangium. In the
sections stained by the PAS technique, several loops showed thickened
capillary walls and double basement membranes (Fig. 18). Tubules
generally were well preserved; 2 small foci showed thickening of the
tubular basement membranes accompanied by atrophy of the epithelium.
The interstitium was expanded in these areas, in part by connective tissue
and by minimal infiltration of mononuclear inflammatory cells. Small
arteries and arterioles revealed prominence of the endothelium, and rare
inflammatory cells could be identified in the intima. The sample processed
for immunofluorescence microscopy contained renal cortex snd 3 glomer-
uli. All glomeruli showed irregular and coarse granular immune deposits
along the peripheral capillary wall and in the mesangium; the deposits
were reactive fur IgG (3+ to 4+/4+), 1gM (3+/4+) (Fig. 1C), and C3(1 +/4+). A similar distribution of deposits was visualized with reagents
specific for kappa and lambda light chains. Isolated glomerular capillary
loops contained small aggregates of fibrin. The electron micrographs
revealed capillary loops occluded by inflammatory cells and deformed red
blood cells (Figs. 2A and 28). The endothelial cells appeared swollen and
had lost most of their fenestrae. Electron-dense deposits were identified in
the lamina rara interna in most capillaries; the deposits had a finely
granular and homogeneous appearance. Ultrastructural characteristics
frequently associated with cryoglobulins such as organized cylindrical
structures, short curved parallel lines, or "fingerprint-like" images could
not be identified with certainty within the deposits. Several loops showed
a thickened capillary wall with double basement membrane, interposition
of cellular projections, and few electron-dense deposits in close apposition
to the original basement membrane (Fig. 28). The epithelial cells showed
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Fig. 1. Light microscopic and immunohistochemical findings in a patient with hepatitis C-associated membranoproliferative glomerulonephntis. A
Glomerulus shows global endocapillary hypercellularity; the inflammatory cells comprise mononuclear cells and polymorphonuclear neutrophils
(arrows). Isolated loops show a thickened glomerular capillary wall (PAS stain). B Glomerulus illustrates a slightly more advanced stage of the injury,
with frequent double-contoured or split basement membrane (single arrows) and moderate hypercellularity and expansion of the mesangium (double
arrows). These abnormalities define the membranoproliferative pattern of injury (PAS stain). C Immunofluorescence micrograph obtained from sections
incubated with FITC-labeled anti-human 1gM; it reveals irregular granular peripheral capillary wall deposits. Some of the deposits show a sharp outer
peripheral boundary, which suggest a subendothelial location. The reactivity for IgG revealed a similar pattern and intensity (not shown), a finding that
suggests the participation of an antibody (IgG) and an anti-immunoglobulin antibody with characteristics of a rheumatoid factor (1gM). The complement
component C3 also was present within these deposits (FITC-labeled anti-IgM). D Giomerulus depicts the peripheral capillary walls with the
characteristic double contours or tram-track pattern (arrows) after silver-methenamine impregnation (Jones' silver stain).
focal degeneration and loss of foot process interdigitations, a change that
was particularly prominent over capillary loops with thickened walls.
The lesion was classified as an immune-complex-mediated glomerulo-
nephritis with a diffuse exudative and membranoproliferative pattern of
injury. The structural and immunohistochemical characteristics and the
distribution of the deposits suggested the possibility of a process with
circulating immune complexes, such as that seen in patients with infections
and persistent or episodic antigenemia. Alternatively, and in the absence
of a demonstrable systemic bacterial, parasitic, or viral infection, the lesion
could be classified under the category of idiopathic membranoprolifera-
tive or mesangiocapillary glomerulonephritis, type I.
Additional laboratory test results included: a negative ASO titer,
negative ANCA serology, trace ANA, negative anticardiolipin antibodies,
and negative hepatitis-B surface antigen and antibody. Hepatitis C
serology was positive, and an HIV test was negative. The cryoglobulins
were considered equivocal. The CH50 was 20 U/mi (reference range, 150
to 250 U/mI), the serum level of C1q was 9 mg/dl (reference range, 35 to
56 mg/dl), the C3 level was 138 mg/dl (reference range, 91 to 198 mg/dl),
and the C4 level was 1 mg/dl (reference range, 26 to 83 mg/dl). The serum
protein electrophoresis showed a faint monocional 1gM kappa band.
Discussion
DR. HELMUT G. RENNK.E (Director, Renal Pathology Laboratory,
Brigham and Women's Hospital; and Associate Professor of Pathol-
ogy, Harvard Medical School, Boston, Massachusetts): Today's
patient illustrates extremely well the fallacy, and often the dan-
gers, of equating a particular lesion or structural pattern of injury
with a disease entity. In the past, before testing for hepatitis C had
been developed [1], this case unquestionably would have been
classified as "idiopathic membranoproliferative glomerulonephri-
tis (MPGN), type I" [2—4], also referred to as mesangiocapillary
giomerulonephritis. Several studies over the past 2 years, how-
ever, have uncovered an association between hepatitis C infection,
the presence of circulating immune complexes often with the
characteristics of cryoglobulins [5—8]; and a membranoprolifera-
tive glomerulonephritis [9, 10]. I am using the term membrano-
proliferative glomerulonephritis here to denote a general pattern
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Fig. 2. Electron microscopic abnonnalities in hepatitis C-associated membranoproliferative glomendonephritis. A High-power electron micrograph shows
characteristic subendothelial electron-deose deposits (marked by the *). The capillary lumen is occupied by a mononuclear inflammatory cell (Mon). The
endothellal cell (End) is focally displaced by the deposits and a new, irregular, and incomplete basement membrane is beginning to be laid down (arrows). Ep
= visceral epithelial cell; US = urinary space (conventional electron microscopy after uranyl acetate and lead citrate staining). B This glomerular capillary loop
illustrates the characteristic findings of the membranoproliferative pattern at a later stage of healing. Few electron-dense deposits are still present in the
expanded subendothelial space (white arrowhead). The endotheial cell is markedly displaced, and it appears to have lost many of its fenestrae. A new basement
membrane is clearly visible (arrows) along almost the entire length of the markedly thickened peripheral capillary wall. A projection of a lysosome-rich cell has
insinuated itself between the displaced endothelium and the original basement membrane (indicated as CI = cell interposition). CL = capillary lumen; Mes
= mesangium; Hp = visceral epithellal cell (conventional electron microscopy after uranyl acetate and lead citrate staining).
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of tissue injury seen in a variety of disease processes that share a
common pathogenetic mechanism, and not to convey the more
restricted meaning of a particular disease entity that causes the
nephrotic syndrome (idiopathic MPGN, type I). Unfortunately,
the precise meaning to be conveyed by the term is not always
made clear either in the medical literature or in biopsy reports.
Confusion similar to that besetting the use of the term membrano-
proliferative glomerulonephritis also surrounds the use of other
renal pathologic terms. Thus, the term focal and segmental
glomerulosclerosis is used not only to describe a particular lesion
seen on renal biopsies of patients with a great number of different
disease entities [11, 12] (the more generalized meaning), but also
to refer to a particular pathologic entity of unknown etiology that
causes the idiopathic nephrotic syndrome [13] (the more re-
stricted meaning). Other examples of confusing terminology are
membranous nephropathy, acute or proliferative glomerulone-
phritis, mesangial proliferative glomerulonephritis, and crescentic
glomerulonephritis. The varying usage of the terms membrano-
proliferative glomerulonephritis, focal glomerulosclerosis, and
others often falls along lines of professional specialties: nephrolo-
gists and internists tend to use these terms with the more
restricted meaning of a particular clinical disease entity. Pathol-
ogists usually apply the same names to indicate a particular
pattern of tissue injury. The ambiguous use of these terms often
can be traced back to the time when a group of patients was split
off from others that presented with a common clinical syndrome
(for example, the nephrotic syndrome) by the occurrence of a
particular lesion or pattern of tissue injury (that is, focal and
segmental glomerulosclerosis). This characteristic finding on bi-
opsy often would correlate with a particular clinical course,
specific prognosis for the renal condition, or particular response
to a therapeutic modality [2]; the newly identified clinicopatho-
logic disease entity then was named according to its apparently
unique histologic features.
Confusing a pattern of injury with the particular disease entity
traditionally defined by such a pattern sometimes has the unin-
tended effect of giving a false sense of security that comes when
one classifies or "pigeonholes" a given patient. Additional sero-
logic or bacteriologic studies that would further define the disease
process and its correct therapeutic approach often are omitted.
This sometimes occurs in patients with a membranoproliferative
pattern of injury secondary to a potentially treatable but con-
cealed infectious process. The misunderstanding also can have
other regrettable consequences. For instance, a systemic vasculitis
can be mistakenly overlooked and the patient not treated appro-
priately because the biopsy showed "focal and segmental glomer-
ulosclerosis." Such a focal scierosing lesion can result from diffuse
epithelial cell injury or in the setting of secondary functional and
structural adaptations that ensue as a consequence of a reduced
number of functioning nephrons, but also as the end result of the
healing process that follows an active focal necrotizing and
crescentic glomerulitis, as seen during the active phase of several
vasculitides.
In most textbooks and in reviews on MPGN, authors tradition-
ally have divided this type of injury into idiopathic and secondary
forms that have a recognizable etiologic agent or a known
associated disease [2—4]. This classification is often of limited
value to the pathologist, who is confronted with this pattern of
injury upon examination of the renal biopsy specimen, when the
clinical and serologic workup of the patient is incomplete. Under
Table 1. Conditions associated with a membranoproliferative pattern of
injury
Immune-complex-mediated disease
Idiopathic forms of MPGN or of unknown association
MPGN type I [14I
MPGN type II or dense-deposit disease and partial lipodystrophy
[15, 16]
MPGN type III (Strife and Anders variant, Burkholder variant)
[17-19]
Autoimmune diseases
SLE [20]
Sjogren syndrome [21]
Rheumatoid arthritis [221
Inherited complement deficiencies, in particular C2 deficiency [23,
24]
Chronic infections
Viral: hepatitis B [25], hepatitis C and cryoglobulinemia type II
(formerly called essential mixed cryoglobulinemia) [9, 10]
Bacterial: endocarditis [26], infected ventriculoatrial (or jugular)
shunt [27], multiple visceral abscesses [26, 281, leprosy [291
Protozoal: malaria (30), schistosomiasis [31]
Other infections: mycoplasma [32]
Miscellaneous
Chronic liver disease (cirrhosis and alpha 1-antitrypsin deficiency)
[33, 341
Chronic and recovered thrombotic microangiopathies
Healing phase of HUSITFP [35]
The syndrome of circulating anti-phospholipid (anti-cardiolipin)
antibodies [36]
Radiation nephritis [37]
Nephropathy associated with bone marrow transplantation [38]
Sickle cell anemia [39] and polycythemia [40]
Transplant glomerulopathy [41]
Paraprotein deposition diseases
Glomerulopathies associated with cryoglobulinemia type I [42, 43]
Waldenstrflm macroglobulinemia [44]
Immunotactoid glomerulopathy [45, 46]
Immunoglobulin light-chain or heavy-chain deposition diseases [47,
48]
Fibrillary glomerulonephritis [45, 46, 49—52]
aNumber in brackets refers to references.
such circumstances, most conditions can reliably be placed into
one of three basic categories, however, depending on the findings
of the renal biopsy (Table 1). This classification is purely descrip-
tive; it is based on a combination of objective findings obtained by
light, immunofluorescence, and electron microscopy that reflect
the fundamental pathophysiologic processes underlying the tissue
injury. The precise classification of a given case and the correct
identification of an associated condition are often only possible,
therefore, after results of additional studies on the patient are
obtained, studies often suggested by the findings of the renal
biopsy.
An in-depth discussion of the clinical manifestations of all
conditions that have been associated with a membranoprolifera-
tive injury clearly is beyond the scope of this discussion. Suffice it
to say that the renal manifestations in most patients with this form
of injury include hematuria, proteinuria, and some degree of
functional impairment. The proteinuria is of variable severity,
often reflecting the extent of the structural changes in the
peripheral capillary wall and the variable obliteration and simpli-
fication of foot processes. A certain percentage of patients within
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all three groups of diseases (Table 1) can present with nephrotic-
range proteinuria or overt nephrotic syndrome. The urine sedi-
ment contains red cells, often red cell casts, and white cells, a
reflection of the inflammatory component seen at some stages of
the development of the disease. The acute nephritic syndrome is
more frequent in patients with dense-deposit disease or early in
the course of a postinfectious condition. Systemic hypertension
can be observed at some stage in the course of the disease, a
complication that is especially prominent in patients with fibrillary
glomerulonephritis [45, 50].
Structural features
The membranoproliferative pattern of injury, defined predom-
inantly by the abnormalities revealed by light microscopic exam-
ination, is characterized by two basic changes: diffuse expansion of
the mesangial elements, and thickening of the glomerular capil-
lary wall. The expansion of the mesangium involves variable
degrees of proliferation of resident mesangial cells, infiltration of
the area by blood-borne mononuclear inflammatory cells [28, 53],
and increased mesangial matrix. These changes can result in an
exaggeration of the lobular pattern of the glomerulus; early
investigators referred to this variant of the process as "lobular
glomerulonephritis." The increase in the thickness of the periph-
eral capillary wall can be segmental rather than global and diffuse
in nature. Capillary loops with a thickened appearance often, but
not invariably, display a characteristic split or reduplicated base-
ment membrane; this feature gives the glomerular capillary wall a
double-contoured, "tram track," or chain-like appearance. Such
changes are particularly well demonstrated when the light micros-
copy sections are stained by Jones' methenamine-silver impreg-
nation (Fig. 1D) or the periodic acid Schiff reaction. The space
between the reduplicated basement membrane, which contains
immune complexes or other plasma-derived protein components
and cytoplasmic extensions of mononuclear cells, does not stain
with these reagents. In all classic textbooks, this latter phenome-
non is referred to as mesangial cell interposition, although direct
or even circumstantial evidence that would indicate that resident
mesangial cells have the capacity to move into the peripheral
capillary wall is lacking. It is reasonable to suggest, instead, that
mononuclear inflammatory cells, which have been demonstrated
in the mesangial regions and within the capillaries of the glomer-
ulus [54] and contribute to the mesangial hypercellularity [55],
also extend into the subendothelial space. These monocytes and
macrophages likely accumulate in the glomerulus, attracted by
chemotactic factors locally generated following the initial injury to
the endothelium or the deposition of immune complexes or
paraproteins within the proximal layers of the glomerular capillary
wall. A membranoproliferative pattern associated with vascular
lesions such as fibrin thrombi in glomerular capillaries, fibrinoid
necrosis of arterial walls, or myointimal proliferation affecting
interlobular arteries strongly suggests one of the conditions
associated with a thrombotic microangiopathy. The presence of
PAS-positive hyaline masses occluding the lumen of glomerular
capillaries or small arteries and arterioles usually indicates in-
volvement by cryoglobulins or other paraproteins. The participa-
tion of light chains in this pattern can be documented reliably by
the use of light-chain-specific antibodies, which probably should
be used routinely during the evaluation of a renal biopsy by
immunofluorescence microscopy. Significant interstitial fibrosis or
inflammation is often seen in patients with systemic light-chain
deposition disease, lupus nephritis, or SjOgren's syndrome. I
would like to emphasize, however, that the light microscopic
findings I have described are generally not unique for any of the
disease entities listed in Table 1.
Immunofluorescence microscopy or immunohistochemical
studies usually help to define more precisely the type of disease
process that has caused the histologic changes I have described.
Depending on the type of disease responsible for this form of
injury, immunoglobulins, complement components, paraproteins,
or products of the coagulation cascade can be demonstrated with
variable intensity, usually along the peripheral capillary wall, but
most notably also in a mesangial distribution. The presence of
granular deposits of polyclonal immunoglobulins and complement
components usually indicates one of the immune-complex-medi-
ated diseases. The presence of fibrin-related antigens, either in
the form of occlusive microthrombi or diffusely outlining the
peripheral capillary wall, suggests a thrombotic angiopathy. The
finding of monotypic light chains or heavy chains alone suggests
the involvement of a paraprotein in the disease process.
The electron microscopic evaluation is often the only reliable
way of correctly identifying the process responsible for the
glomerular disease. In the immune-complex diseases, the endo-
thelial cell, normally attached to the basement membrane by a
very thin lamina rara interna, is separated from this structure by
an expanded subendothelial space that contains cellular projec-
tions (interposition of mononuclear cells) and discrete electron-
dense deposits. A new and often irregular and incomplete base-
ment membrane is present immediately under the displaced
endothelium (Fig. 2). Mononuclear and polymorphonuclear in-
flammatory cells often are seen within the capillaries. The chronic
thrombotic angiopathies also are characterized by a widening of
the subendothelium, which contains finely granular and electron-
lucent, "fluffy" material, occasional strands of cross-linked fibrin,
platelet fragments, cell membrane debris, and other poorly iden-
tified elements; prominent interposition of cellular elements and
a newly formed second basement membrane also are present with
this form of injury. In the deposition diseases, the peripheral
capillary wall is thickened more uniformly by irregular aggregates
of fine, granular, electron-dense material (light-chain-deposition
diseases), amyloid-like fibrillary deposits (fibrillary glomerulone-
phritis), or highly organized microtubular elements (immunotac-
toid glomerulopathy, Waldenstrom's macroglobulinemia, and
cryoglobulinemia). Often, this material also infiltrates the base-
ment membrane diffusely; the lamina densa appears less well
defined and often is destroyed. Classic double-contoured base-
ment membranes and cellular interposition are less obvious in the
deposition disease group. Foot processes show degenerative
changes that vary greatly among cases; some degree of simplifi-
cation of the normal interdigitating arrangement of the foot
processes and an increase in the number of cytoplasmic vacuoles,
lysosomes, and cell surface microvilli are routinely observed. In all
cases with a membranoproliferative pattern of injury, one ob-
serves signs of endothelial cell damage with loss of fenestrae and
swelling of the normally tenuous cell body. The endothelial cell
also can be missing altogether during the more active phase of a
thrombotic angiopathy. The mesangium is also expanded by
electron-dense deposits or fibrillaiy material, a variable increase
in amorphous or finely fibrillar extracellular matrix material, and
an increase in cellular elements.
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Pathogenesis
Let me repeat: three fundamentally different pathologic pro-
cesses can result in a membranoproliferative pattern of glomeru-
lar injuly: disease processes with circulating immune complexes,
thrombotic angiopathies, and some paraproteinemias and depo-
sition diseases (Table 1). The basic pathologic processes common
to all the diseases associated with this pattern of injury include
first, a form of active injury to the more proximal layers of the
glomerular capillary wall and the mesangium, often accompanied
by active inflammation, and second, a phase of cellular prolifera-
tion and repair that results in expansion of the mesangial matrix
and reduplication of the basement membrane.
During the active phase of the injury, the endothelial cell often
is directly damaged by toxins or products of complement activa-
tion and by the ensuing accumulation and infiltration of blood-
borne inflammatory cells. Although inflammatory cells are rea-
sonably efficient in removing immune complexes from the more
proximal layers of the glomerular capillary wall [561, in some
capillary loops immune complexes trapped upstream of the
lamina densa may prevent the regenerating endothelium from
making appropriate contact with the original basement mem-
brane. Similarly, the regenerating endothelium may be prevented
from reaching the necessary matrix components normally present
in the lamina densa of the basement membrane by paraproteins
deposited in the lamina rara interna, fibrin, cell, and platelet
debris, or other products produced during activation of the
coagulation cascade. Under such adverse conditions, the endothe-
hal cell is stimulated to generate a new basement membrane
separated from the original lamina densa by the deposited
material and trapped inflammatory cells. The endothelium's
ability to generate a basement-membrane-like structure has been
well documented in cell culture experiments.
At different stages of the disease process, either the inflamma-
tory attack or the repair process can dominate. As a result of these
two activities, some renal biopsies demonstrate more hypercellu-
larity and active inflammation (the proliferative or exudative
component of the pattern), while the glomeruhi during later stages
show more signs of tissue repair. This latter phase is evidenced by
thickening of the peripheral capillary wall with characteristic
double-contoured or split basement membranes and an expansion
of the mesangium by infiltrating mononuclear cells and prolifer-
ated resident mesangial cells and by an increase in extracellular
matrix.
Immune-complex-mediated diseases. The active tissue injury in
immune-complex-mediated diseases occurs after in-situ formation
of immune complexes or deposition by entrapment of pre-formed,
circulating complexes within the lamina rara interna or subendo-
thelial layer of the glomerular capillary wall. Most patients
probably suffer from persistent or episodic antigenemia derived
from an infectious agent. A similar process of immune-complex
deposition also probably occurs in the idiopathic membranopro-
liferative glomerulonephritides types I and III, although we have
no clue as to the nature or source of the antigens involved in these
diseases. As Appel recently pointed out in an editorial comment
[57], the precise identity of the antigens involved in any of the
glomerular diseases that occur in association with a known
infectious process is still unknown; most secondary forms of
membranoproliferative glomerulonephritis are defined exclusively
by the frequency of the temporal association with a particular
infectious process. Complement components are invariably found
within the glomerular capillary wall in these patients. One can
assume that various peptide fragments, such as C3a and C5a, or
heteromultimers that result from complement activation, such as
C5-9, are locally generated and act respectively as chemotactic
factors for inflammatory cells or as mediators of direct injury to
the cell membrane of endothehial, visceral epithelial, and mesan-
gial cells.
We have gained many insights into the pathogenesis of these
disorders over the past few decades from the analysis of various
models of experimental serum sickness. Most active models
involve single or repeated injections of a foreign protein that
serves both as an immunogen and a target for the subsequently
produced antibodies. Immune deposits in the tissues result from
entrapment within the walls of arteries and capillaries of immune
complexes assembled in the circulation during the phase of active
immune elimination of the circulating antigen [58]. Alternatively,
immune complexes in the tissues also can result from the inter-
action of the foreign antigen planted at such sites during the
pre-immune phase and antibodies delivered to such sites after the
immune elimination of the antigen is completed and free antibod-
ies are available in circulation and in the tissues. Immune
complexes within the lamina rara interna and in the mesangium
also can be induced by sequential administration of antigens and
specific isologous or heterologous antibodies [56, 59, 60]. Some
glomerular abnormalities also can be reproduced in animals by
the administration of immune complexes produced in the test
tube by the interaction of antigens of defined physicochemical
characteristics and specific antisera or purified fractions of immu-
noglobulins; these experimental diseases constitute the passive
models of serum sickness [61].
The glomerular capillary wall functions as an effective size- and
charge-selective filter [62, 63]. Negatively charged residues are
concentrated predominantly on endothelial and epithelial cell
surfaces and in both laminae rarae [62]. Antigens, antibodies, and
immune complexes with positively charged residues therefore can
interact with these negatively charged structural elements of the
capillary. Using ultrastructural tracer studies, several investigators
have also concluded that the lamina densa and the filtration slit
diaphragms can restrict the filtration of macromolecules on the
basis of their size [62, 64]. One can reasonably assume, therefore,
that several molecular characteristics of the antigen, the antibody,
or the immune complexes are important factors that determine
the site of localization of the deposits. The site of immune-
complex deposition or assembly in turn determines the clinical
and structural expression of the disease. Molecular characteristics
that are relevant in this context include the charge and the
effective filtration size of the antigen or the pre-formed com-
plexes, the antibody affinity and avidity, and other physicochemi-
cal characteristics that endow some antigens with special affinity
for extracehlular matrix components or with lectin-hike properties.
A substantial body of often conflicting experimental data deals
with the effect of the molecular charge of antigens, antibodies, and
immune complexes on the resultant disease. The bulk of the
experimental evidence indicates that models involving sequential
administration of cationic macromolecular antigens and specific
antibodies and acute serum sickness models induced with cationic
antigens produce a membranous pattern of injury with diffuse
subepithehial electron-dense deposits [56, 65, 66]. Active inflam-
mation can occur transiently during the first few hours after
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induction of the disease but is generally absent. Clinically these
models are characterized by significant proteinuria and a normal
glomerular filtration rate [56, 65]. Removal of these subepithelial
deposits is slow, and the proteinuric phase lasts several months
after a single episode of immune-complex deposition [56]. In this
setting, the damage seen in the visceral epithelium is likely the
result of complement activation and generation of C5-9 near the
podocytes, as demonstrated for the Heymann model of membra-
nous nephropathy by Salant and Couser and their collaborators
[67, 68]. Immune-complex-disease models with epimembranous
deposits show no signs of active inflammation; a potential gradient
of complement-derived chemotactic agents (C3a and C5a) is not
likely to be generated upstream given the high unidirectional
convective flow across the glomerular capillary wall driven by the
imbalance of Starling's forces [56, 69]. The absence of an inflam-
matory response in disease models of the membranous type with
immune complexes present exclusively in the lamina rara externa
also could be ascribed to a failure of the endothelium to be
actively engaged in the process or to sustain significant damage,
because immune complexes and complement activation occur at a
distance in the lamina rara externa of the glomerular capillary
wall. Factors that could upregulate specific inflammatory adhe-
sion molecules on the endothelium [70] are not likely to reach, in
a retrograde fashion, the inner layers of the capillary wall. The
lack of glomerular inflammation is also in keeping with the
relatively bland urinary sediment observed in patients with a
membranous pattern of injury.
Active serum sickness models that utilize negatively charged
antigens [65, 71] and passive models induced with pre-formed
immune complexes with weakly cationic, anionic, or heteroge-
neous molecular charge [72] result in mild glomerular pathology
with electron-dense deposits seen predominantly in the mesan-
gium and, more rarely, in the subendothelial space. Dense depos-
its within the subendothelial layer of the capillary wall often result
from an in-situ mechanism of immune-complex formation. Such
immune complexes can be induced with greater consistency with
antibodies specific for local, endothelium-derived antigens [73] or
with antibodies directed against an exogenous antigen with lectin-
like activity planted on or near the endothelium [60, 74]. In-vitro
studies also have shown a special binding capacity of DNA for
collagen molecules [75]; such interactions also could occur be-
tween the glomerular capillary wall and viral RNA present in the
circulating immune complexes detected in patients with hepatitis
C-associated cryoglobulinemia [6, 9, 76], the presumed cause of
renal injury in today's patient.
The size of immune complexes is in direct proportion to the
molecular weight of the reactants and the number of molecules
within the complex; the latter, in turn, is determined by the
relative concentration or ratio of antigen to antibody in the
solution and in the circulation. The level of antibody in the
circulation is a function of the animal's immune response and
antibody production and the rate of antibody disappearance due
to binding to circulating or tissue-bound antigen. Animals with
high levels of antibody production, and presumably with large
circulating immune complexes, suffer minimal or no renal disease
[77]. Preliminary studies from our laboratory performed in an
active serum sickness model using cationic and native bovine
serum albumin in rats have shown that continuous infusion of the
antigen via osmotic minipumps does not result in immune-
complex deposition in the kidney [78]; immune complexes that
form under these circumstances can be expected to be large, as
they are formed continuously in antibody excess. An identical
daily antigenic load given as a single intravenous bolus injection
yields a typical membranous pattern of injury when the cationic
antigen is used. Intermittent (daily bolus) injection of native,
negatively charged bovine serum albumin produces a membrano-
proliferative type of injury with subendothelial and mesangial
electron-dense deposits, focal cellular interposition in the periph-
eral capillary wall, and basement membrane splitting [78].
The lack of immune-complex deposition and subsequent injury
in the tissues in experimental settings that favor large immune-
complex formation in the circulation has largely been ascribed to
an effective removal of circulating complexes by the mononuclear
phagocyte system of the liver, spleen, and bone marrow. This
clearing function is greatly assisted in rodents by platelets and in
primates by erythrocytes and leukocytes with CR1 complement
receptors [80]. These cells effectively shuttle immune complexes
between the peripheral circulation and the organs that are
responsible for immune-complex degradation.
Immune complexes of intermediate size usually remain within
the proximal layers of the glomerular capillary wall and in the
mesangium [81] and potentially could induce an inflammatory
response. Only the smallest immune complexes assembled in
antigen excess or prepared with antibodies of low affinity can filter
beyond the lamina densa and form epimembranous electron-
dense deposits [82]. It has been argued, however, that all subep-
ithelial deposits result from an in-situ assembly of complexes [83]
and that small, soluble immune complexes trapped in the lamina
rara interna are likely to dissociate before traversing the lamina
densa and re-associating in the lamina rara externa. In a series of
elegant studies, Gallo and collaborators have clearly shown that
small, cross-linked cationic immune complexes, and hence non-
dissociating complexes, can filter beyond the lamina densa and
induce a membranous form of injury [72, 84]. These findings are
in keeping with the observation that cationized ferritin with a
molecular weight close to 500 kD and equivalent in size to an
Ag2:Ab2 immune complex filters across the lamina densa and
accumulates in the lamina rara externa [62].
It is also conceivable that several molecular characteristics—
such as charge, size, and affinity of the antigen or the circulating
immune complex for components of the glomerular capillary
wall—act in concert to determine the likelihood that deposits will
form in the lamina rara interna. Antigens and immune complexes
that localize in the subendothelial layer of the basement mem-
brane are likely to have a net positive charge or a strong binding
capacity for elements of the lamina rara interna. Such character-
istics would be essential to overcome the effective charge-selective
barrier offered by the negatively charged endothelium. Further-
more, such antigens or immune complexes also need be of
relatively large size to be restricted from filtering beyond the
lamina densa. The antigen or an immune complex initially depos-
ited in the more proximal layers of the glomerular capillary wall
then could interact with additional free antigen, antibodies, or
antigen-antibody complexes [85], or bind anti-idiotypic antibodies
and rheumatoid factor (antibodies, usually of 1gM class, directed
against the Fe portion of IgG) and elements of the complement
system.
Immune complexes deposited or generated in the more proxi-
mal layers of the glomerular capillary wall, that is, on or near the
endothelium and in the subendothelial space of the glomerular
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capillary wall, usually elicit a brisk but transient inflammatory
response [56]. Animal models with subendothelial immune depos-
its also are characterized by an early phase of platelet accumula-
tion [56, 86], significantly less (or no) proteinuria compared with
models of subepithelial immune deposition, and often an early
phase of diminished glomerular filtration rate [56]. The removal
of subendothelial deposits is usually swift, occurring within a few
hours or days in disease models induced by a single episode of
immune-complex formation [56].
The idiopathic type-Il membranoproliferative glomerulone-
phritis, or dense-deposit disease, is in many aspects a completely
different process than the immune-complex-mediated entities I
just described. It is an autoimmune disease with circulating
antibodies directed at C3bBb, the alternate pathway C3 conver-
tase; the autoantibody is usually an IgG, also known as the C3
nephritic factor. The antibody stabilizes the enzyme, prevents its
normal degradation, and increases complement activation and
consumption. In addition, there is a decrease in hepatic synthesis
of complement of poorly understood pathogenesis. Electron-
dense material is deposited in the basement membranes of
glomeruli, tubules, and vessels. The nature of the dense material
deposited in the capillary is unknown [87].
Chronic thrombotic microangiopathies. The membranoprolifera-
tive pattern of injury also develops in some patients during the
recovery phase of acute thrombotic microangiopathies or during
the course of some of the more indolent forms of these disorders
(see Table 1). The term "thrombotic microangiopathy" is used
here only to indicate a type of lesion that occurs in several
conditions having a common pathophysiologic mechanism, rather
than to define a particular clinical entity. The pathophysiology of
these processes is somewhat confusing [88]. An important step in
the pathophysiology is platelet activation and consumption. The
mechanism by which this occurs is not completely understood. In
general, three basic mechanisms have been postulated as operat-
ing in these clinical settings: endothelial cell injury, the presence
of a platelet aggregator in the circulation, and a reduction in a
normally occurring platelet inhibitor.
Direct injury to the endothelial cell, or indirect injury via
neutrophil activation [89], is thought to be responsible for the
injury in the childhood form of the hemolytic-uremic syndrome
(HUS) associated with E. coli infections (particularly 0157:H7
type), radiation nephritis, the nephropathy associated with bone-
marrow transplantation, and several forms of cancer and antire-
jection therapy. An immunologic basis for endothelial cell injury
also has been proposed, in particular for the conditions associated
with organ rejection and in some children with HUS [90]. Some
patients with these disorders have an increased circulating level of
a platelet aggregating factor, such as unusually large von Wille-
brand factor [91], a circulating cysteine protease (calpain) [92], or
increased levels of plasminogen activator inhibitor, type 1 [93].
Finally, a decreased level of a normal inhibitor of platelet
aggregation also could explain the occasional reversal of the
disease in patients after plasma infusion [94].
Paraprotein deposition diseases. A membranoproliferative pat-
tern of injury is also a common structural finding in paraproteine-
mias with renal involvement (see Table 1). In renal biopsies of
patients with these conditions, the glomeruli often show promi-
nent expansion of the mesangium by excess matrix accumulation,
mild to moderate mesangial hypercellularity, and variable thick-
ening of the peripheral capillary wall. The distinctive nodular
lesion often associated with these conditions has a striking resem-
blance to the changes seen in diabetic nephropathy [47]; thick-
ened basement membranes are routinely seen, but duplicated or
double-contoured basement membranes are infrequent.
In many patients with this category of disorders, the overpro-
duction of light chains, heavy chains, or a fully assembled but
abnormal immunoglobulin is the result of a plasma cell dyscrasia
or an overt multiple myeloma or B-cell lymphoma; in others, a
neoplastic source is not immediately apparent at the time of the
renal involvement [47]. It is not clear why only a small proportion
of patients who overproduce light chains manifest systemic dep-
osition diseases. Furthermore, the molecular characteristics that
would predict whether a given light chain is amyloidogenic (most
often lambda chains) or would result in non-fibrillary, fine, and
irregular dense deposits (most often kappa chains) are unknown
[48, 951. The biochemical and molecular analysis of light chains
from patients with deposited paraproteins has not yielded a
unique structure or sequence that would explain a potential
affinity of these light chains for components of the extracellular
matrix, and the basement membrane in particular (reviewed in
Ref. 96). Likewise, the mechanisms and mediators or growth
factors involved in the proliferation of cells and the overproduc-
tion of matrix components remain unexplored.
The nature and sources of the paraproteins responsible for
fibrillary glomerulonephritis are not known. Its structural features
and clinical associations have led to the suggestion that this entity
is distinct from immunotactoid glomerulopathy [46, 97, 98].
Others have argued strongly that these two disorders merely
represent different expressions of a similar biochemical abnormal-
ity [45, 99]. The deposits in fibrillary glomerulonephritis usually
are reactive for polyclonal IgG [45, 46, 49, 52, 100]. Although the
fibrils in this condition are thought by some to derive from an
abnormal immunoglobulin, the infrequent observation of an
associated plasma cell dyscrasia strongly argues against this
possibility [46, 50]. Such an association, however, does seem to
exist in patients with immunotactoid glomerulopathy [46, 101].
The relatively constant finding of IgG4 in the glomerular deposits
in a recently published series of patients with fibrillary glomeru-
lonephritis again has raised the possibility of a neoplastic B-cell
origin of the protein [52]. The fibrillary deposits, however, are
usually not monoclonal, as both lambda and kappa reactivities are
present simultaneously. The alternative possibility—that IgG4, a
negatively charged immunoglobulin, binds avidly to fibrils on the
basis of charge interactions—also should be considered seriously.
A strongly cationic fibrillary component also would explain the
high predilection of the deposits for the glomerular capillary wall.
Summary
The term membranoproliferative glomerulonephritis has been
used in the literature and in practice to convey several different
meanings: it can describe a pattern of structural glomerular
abnormalities or refer to an immune-complex-mediated disease
process of unknown cause, often identified as idiopathic mem-
branoproliferative glomerulonephritis. The structural changes
that characterize this form of injury include an increase in the
number of cells within the glomerular capillaries or in the
mesangium and an increase of the extracellular matrix. These
changes often result in expansion of the mesangium, accentuation
of the lobular glomerular pattern and formation of distinctive
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nodules, and the production of double-contoured basement mem-
branes. These structural glomerular abnormalities often compli-
cate the course of diseases of totally diverse pathogenesis with
different clinical manifestations. Common to all these processes is
an acute or persistent injury to the more proximal layers of the
glomerular capillary wall and the mesangium with subsequent
healing or repair. A component of active inflammation or micro-
vascular thrombosis is present during the early phases of the
disease process, while an increase in extracellular matrix and
basement membrane reduplication characterizes the more estab-
lished and chronic lesions. These changes are nonspecific at the
light microscopic level.
Three groups of diseases should be considered in the differen-
tial diagnosis of patients whose biopsy findings reveal a mem-
branoproliferative pattern of glomerular injury. (1) Immune-
complex-mediated diseases. Most notable in this group are several
chronic or persistent infectious processes that result in glomerular
lesions indistinguishable from those in patients with idiopathic
type-I membranoproliferative glomerulonephritis. (2) Chronic
and healed thrombotic microangiopathies. (3) Paraprotein depo-
sition diseases. The precise diagnosis of these diseases often
requires thorough immunohistochemical and ultrastructural stud-
ies or additional serologic and chemical laboratory tests.
Questions and answers
DR. JOHN T. I-IARRINGT0N (Academic Dean, Tufts University
School of Medicine, Boston, Massachusetts): You began by discuss-
ing patients with hepatitis C and cryoglobulinemia. What is the
"gold standard" for making a diagnosis of a disease due to
cryoglobulinemia? Is the diagnosis based on serum findings, or is
it based on tissue examination? My followup question is: In
patients with hepatitis C and MPGN who have neither tissue nor
serologic evidence of cryoglobulins, do you think we're simply
missing the ciyoglobulins?
DR. RBNNKE: The issue of a "gold standard" for making the
diagnosis of a disease due to cryoglobulinemia has not been
resolved entirely. In part, this is due to a scarcity of longitudinal
serologic results and a lack of ultrastructural examination of the
tissue in a sufficient number of patients that would allow us to
correlate these findings. The reports in the literature often deal
either with the serologic and clinical findings or the morphologic
manifestations, but seldom with both. I believe a tissue diagnosis
is not always necessary for us to make the diagnosis of a
cryoglobulinemia-induced renal disease, particulary when con-
vincing serologic documentation is available in a patient with a
clear and consistent clinical picture. I also have seen renal biopsies
with ultrastructural findings characteristic for cryoglobulins and a
negative cryoprecipitation test done shortly after the tissue had
been obtained. In such cases I often have assumed that the
appearance of the cryoglobulin in the circulation must have been
transient. Your followup question has not been answered com-
pletely either, because the association among hepatitis C infec-
tion, cryolobulinemia, and glomerulonephritis has only been
recognized recently. However, I do not think we are simply
missing the cryoglobulins in the serum of some patients with
hepatitis C-associated glomerulonephritis. I cannot discount the
possibility that in some patients the production of cryoglobulins
might not reach a level in the serum that would be easily detected
by standard laboratory techniques. Other patients might produce
a monoclonal 1gM antibody with the characteristics of "rheuma-
toid factor" but without the ability to induce the immune complex
to precipitate in the cold. Alternatively, it is also likely that some
patients respond to the hepatitis C virus infection without pro-
ducing this anti-immunoglobulin 1gM antibody. Such patients
then could develop an immune-complex disease similar in nature
to the glomerulonephritis seen in the course of other chronic or
persistent infections. Such patients would not have detectable
circulating cryoglobulins and would not present with the unique
clinical findings associated with cryoglobulinemia or the peculiar
ultrastructural features within the electron-dense deposits.
DR. HARRINUTON: I am fascinated by your studies showing that
continuous infusion of bovine serum albumin resulted in no
detectable structural abnormalities. Recently several papers have
suggested that immunoglobulin infusions could benefit various
glomerular diseases. A recent article in fact argued that treatment
with high-dose immunoglobulin favorably affected Henoch-
SchOnlein purpura [102]. Can you connect your experimental
observation with those preliminary, clinical results?
DR. Reri: It has been proposed that patients with IgA
nephropathy have an underlying relative immune deficiency state,
as evidenced by a partial deficit of IgG antibodies (mainly
affecting the IgGI subclass) [102] and a high renal allograft
survival rate [103]. The administration of immunoglobulins is
intended to correct this deficit and modify the basic mechanism
underlying the disease process. Some have suggested that IgA
nephropathy could result from the deposition in the mesangium
of immune complexes that develop in response to an uncontrolled
mucosal immune response to chronic exposure to an environmen-
tal or dietary antigen. If one assumes that the aforementioned
suggestions are correct, I could argue that immunoglobulin ther-
apy results in the formation of large IgG complexes (formed in
great antibody excess) that can effectively be cleared by the
reticuluni/phagocyte system and thereby result in removal of the
offending antigen(s) from the circulation. The deposition of
IgA-containing immune complexes then could be avoided. There
is, of course, no direct evidence for this hypothesis.
DR. AJAY K. SINGH (Division of Nephrology, New England
Medical Center, Boston, Massachusetts): As you know from John-
son's work in Seattle and Border's work in Utah, in the Thyl.1
model of mesangioproliferative glomerulonephritis, binding of
IgG autoantibody to Thyl.1 on the surface of mesangial cells leads
to mesangial cell injury and the induction of a variety of growth
factors, including PDGF and TGF/3. What can you tell us about
the profile of growth factors when the endothelium is the initial
target of immunologic injury, as in MPGN? Specifically, have
there been in-situ hybridization analyses of cytokine gene expres-
sion in renal biopsies from patients with MPGN?
Dn. RENNKE: Most of the experimental work you mention has
concentrated on a model of mesangial injury induced by cytotoxic
antibodies. I am not aware of any study in human membranopro-
liferative glomerulonephritis or in an appropriate animal model
that has looked for the expression of growth factors or cytokine
production. The exact source of cytokines and growth factors
could be difficult to pinpoint in such a study, as platelets and
monocytes/macrophages are important participants in the disease
process. Under appropriate stimulatory conditions, these cell
elements release a number of cytokines and growth factors. The
relative contribution of the intrinsic glomerular cells in the
production of such factors might be obscured, unless cumbersome
electron microscopic studies are performed.
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DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Your definition of the membranoproliferative
pattern emphasizes the endothelial injury and the subendothelial
site of deposits or accumulation of material. What term do you
use to classify the pattern of injury frequently observed in patients
With lupus in which the renal lesion is characterized by the
superimposition of a proliferative and a membranous lesion?
DR. RENNKE: The situation you mention occurs relatively
frequently. The clinical course in such patients is often character-
ized by many months or even years of proteinuria or the nephrotic
syndrome with a bland urinalysis followed by a more recent
decline in glomerular filtration rate and the appearance of
significant hematuria and red cell casts in the urine sediment. I
personally refer to such a process as "lupus nephritis with a
membranous and proliferative pattern of injury." In such cases we
find not only prominent and diffuse subepithelial electron-dense
deposits, as one expects in a membranous pattern of injury, but
also subendothelial deposits accompanied by accumulation of
inflammatory cells within the capillaries or in the expanded
mesangial compartment. As you imply in your question, in such
patients we assume that a change in the type and specificity of the
antibodies produced in the patient leads to a more aggressive
form of glomerular injury, superimposed on a background of
membranous lupus nephritis.
DR. NIcoLAos E. MAD!AS (Chief Division of Nephrology, New
England Medical Center): In some patients with type-I MPGN and
most of those with type-TI, a renal biopsy reveals only complement
but no immunoglobulin. What is the significance of this observa-
tion regarding pathogenesis?
DR. RENNKE: I do not know the exact significance of this
observation, and there is no good explanation in the literature for
this phenomenon. The apparent loss of tissue-bound immuno-
globulin also occurs in patients with other postinfectious glomer-
ulonephritides, in particular, in patients with serologically docu-
mented poststreptococcal glomerulonephritis. These patients
often are biopsied relatively late in the course of the disease.
Characteristic electron-dense deposits, or "humps," are seen
along the glomerular capillary wall by electron microscopy, but by
immunfluorescence microscopy one is able to uncover comple-
ment components but no immunglobulins. In the past, I have
interpreted such findings as indicative of a relatively early loss of
the antigenicity of the immunglobulin(s) in the setting of active
inflammation. It is possible that complement components, for
reasons unknown to me, retain the antigenic structure for a longer
time.
DR. MADIAs: Do we know anything about the composition of
dense deposits in type-Il MPGN? Specifically, do they contain C3
nephritic factor? Also, is there evidence for the pathogenicity of
this factor? Can it exist in the circulation in the absence of
nephritis?
DR. RENNKE: We do not know the exact composition of the
dense deposits. A recent review suggests that the dense deposits
have a biochemical composition that resembles the normal base-
ment membrane, and that they probably contain glycoproteins
and lipids rich in unsaturated fatty acids [4]. Immunoglobulins, C3
nephritic factor, complement, and binding sites recognized by
Goodpasture antibodies have not been identified within this
material. The lack of a definitive answer to this question is not
entirely surprising, because we do not know the exact biochemical
composition of most antigen-antibody complexes that localize in
the glomerulus, as emphasized recently by Appel [571.
The pathogenicity of the autoantibody associated with dense-
deposit disease, the C3 nephritic factor, was believed to relate to
the capacity of this antibody to block the enzymatic function of the
C3 convertase of the alternative complement pathway. How such
a biochemical defect with its ensuing consequences on comple-
ment activation could result in tissue injury so characteristic for
this disease is entirely unknown. An animal model for dense-
deposit disease does not exist. Several reports of conditions with
detectable C3 nephritic factor but without nephritis have ap-
peared in the literature; these include herpes gestationis [104],
meningococcal meningitis, and chronic urticaria with mild leuko-
cytoclastic vasculitis [105, 106]. It even has been suggested that the
appearance of C3 nephritic factor is a normal physiologic event
[107].
DR. BRJ PEREIRA (Division of Nephrology, New England
Medical Center): In the hepatitis C-associated nephritides, why do
some people develop MPGN, some membranous, and others IgA
nephropathy?
DR. RENNKE: The answer to your question has not been
elucidated, It certainly has to do with the appropriateness of the
immune response to the hepatitis C virus, which varies among
patients. Some patients develop an immune response capable of
effectively eradicating the virus from the system. Other patients
cannot do this, and the infection persists in the liver with
continuous hepatic damage. Products of the virus can enter the
circulation and set the stage for an immune-complex-mediated
disease. As is the case for other viral infections, and in particular
for hepatitis B infection, the renal condition most often associated
with persistent antigenemia is a membranoproliferative glomeru-
lonephritis. The proposed mechanisms responsible for the devel-
opment of a membranous glomerulopathy in response to a viral
infection are different from those that produce MPGN. It is likely
that the virus induces a limited autoimmune response in some
human hosts. Autoantibodies could develop through so-called
molecular mimicry, whereby a viral antigen induces the formation
of antibodies that cross-react with an endogenous antigen on the
glomerular visceral epithelial cell. Alternatively, such autoanti-
bodies could be the result of a nonspecific polyclonal B-cell
stimulation by the virus. The target of such autoantibodies is
antigens normally expressed on the cell surface of the glomerular
visceral epithelial cell. Immune complexes form in situ by the
interaction of endogenous epithelial cell antigens and filtered
autoantibodies [83]. A third alternative mechanism for the devel-
opment of a membranous pattern of injury in the setting of a
persistent viral infection implies the participation of a cationic
viral antigen in the formation of subepithelial complexes. As I
discussed before, such a mechanism would require that the
exogenous antigen be planted in the subepithelial space of the
glomerular capillary wall during phases of relative antigen excess
in the circulation. The precise mechanism reponsible for a virus-
induced membranous nephropathy in humans has not been
elucidated to date, and the possibilities I mentioned remain
speculative.
DR. PEREIRA: Although the hepatitis C virus has not yet been
discovered, a fair length of the genomic sequences is known. Do
you know which particular antigens are associated with these
cryoglobulin deposits? Is there a possibility that only patients who
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produce non-neutralizing antibodies are vulnerable to glomerulo-
nephritides?
DR. RENNICE: Your speculation, that only patients who produce
non-neutralizing antibodies develop some form of glomerular
injury, is probably correct, at least for the membranoproliferative
type of disease, a condition that depends on the persistence of an
antigen or immune complexes in the circulation. At present, not
enough information is available on the immune status of patients
with hepatitis C infection and membranous nephropathy for us to
determine whether this complication can develop after the patient
has successfully eradicated the viral infection through an effective
antibody response.
DR. PEREIRA: Does treatment with interferon modulate the
histology in hepatitis C-associated glomerulonephritides? Is the
renal injury worse in those who have liver disease compared with
those who don't have liver disease?
DR. RENNKE: I do not know whether the occurrence of renal
disease correlates with the severity of the liver damage. Treatment
with interferon appears to arrest the renal disease, at least
temporarily [9].
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): Your classification of patients with membranoprolif-
erative glomerulonephritis contains a wide range of urinary
findings associated with these diseases—from a very active ne-
phritic-type sediment to a relatively bland sediment. Could you
comment on the morphologic findings that lead to the differing
urinary sediment composition?
Dn. RENNXE: My own bias would suggest that patients with
active inflammation, defined by the presence of polymorphonu-
clear and mononuclear inflammatory cells within the capillaries,
would tend to have a more active urine sediment, occurring
predominantly during the phases of active immune-complex dep-
osition. The sediment would become less active during phases of
repair; morphologically this stage of the disease would be char-
acterized by a lack of active inflammation within the capillary
loops, frequent double-contoured basement membranes, and
moderate mesangial hypercellularity. A patient with this pattern
of injury can be anticipated to have heavy proteinuria or the
nephrotic syndrome. Unfortunately, a rigorous study that corre-
lates the urinary sediment findings and the biopsy abnormalities in
membranoproliferative glomerulonephritis has not been per-
formed to my knowledge.
DR. MrnAs: You expressed your conviction that the interposed
cells between the reduplicated basement membrane in MPGN
represent blood-borne monocytic cells rather than glomerular
mesangial cells. Has this issue been examined carefully using
appropriate cell markers?
DR. RENNKE: This issue has not been examined very carefully.
Most studies performed on biopsy specimens from patients with
membranoproliferative glomerulonephritis and on experimental
animals have employed immuno-enzymatic techniques at the light
microscopic level. These techniques have the shortcoming of a
limited resolution. Identification of the cells within the capillary
wall at the ultrastructural level by appropriate markers is clearly
required before we can settle this issue.
DR. HARRINGTON: Has anyone tried to block ICAMs in an
experimental model of MPGN?
DR. RENNXE: I am not aware of such a study.
DR. LEvEY: You mentioned that cryoglobulins can present
ultrastructurally in a number of different ways, one of which is
with a fingerprint pattern. A fingerprint pattern also has been
described in patients with lupus [108]. Do these patients also have
cryoglobulins?
Dn. RENNKE: It has been my experience that many patients with
lupus nephritis who have electron-dense deposits with fingerprint
patterns also have circulating ctyoglobulins. Often these patients
also present on biopsy with cryoprecipitates within capillary
lumena, the so-called microthrombi of active lupus nephritis.
Unfortunately, I have not rigorously recorded these observations,
and I have not seen a published study that has addressed this
association.
DR. MAmAs: Is there evidence for platelet involvement in the
idiopathic or immune-complex types of MPGN, as opposed to
that associated with thrombotic syndromes?
DR. RENNICE: Several investigators have reported the finding of
platelets within glomerular capillaries during the early phases of
experimental immune-complex-mediated glomerulonephritis [56,
60, 86]. Most of these studies, however, were performed on
models of acute glomerulonephritis and not in experimental
serum sickness, the more appropriate model of membranoprolif-
erative glomerulonephritis. The evidence that platelets are in-
volved in membranoproliferative glomerulonephritis in humans is
indirect and comes mostly from studies on platelet survival and
from clinical trials on the effect of platelet-inhibitor therapy
(reviewed in Ref. 4).
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